The stock cost of Big Rock Partners Acquisition (NASDAQ: BRPA) increased by 88.01% as it went from a close that is previous of19.19 to $36.08. There isn’t any direct news through the business, however the stock cost seems to be driven by a rumor that is certain.
Back December, Big Rock Partners Acquisition announced a merger with NeuroRx, which really is a clinical-stage molecule that is small enterprise that develops novel therapeutics for the treating central nervous system problems and life-threatening pulmonary diseases, Meta News reported.
In September 2020, NeuroRx had established a partnership that is commercial Relief Therapeutics Holding AG for the international commercialization of RLF-100 (aviptadil acetate) (now reformulated as ZYESAMITM), that is an FDA Fast Track-designated, investigational, precommercial drug for COVID-19 related respiratory failure. Included in the partnership Relief Therapeutics might have the right to fund all formulations and development that is medical of for remedy for respiratory illness in return for a predetermined share of earnings.
This Monday, Big Rock Partners Acquisition shareholders are increasingly being expected to approve associated with business combination at the conference that is yearly of of Big Rock Partners Acquisition Corp.
And there’s been plenty of chatter on stock trading community forums that NeuroRx’s COVID-19 drug might be crisis that is nearing Authorization (EUA) approval by the Food and Drug management (Food And Drug Administration). Today these rumors appear to be the catalyst for the stock cost enhance. The stock cost of Big Rock Partners Acquisition.